NCT01184989 - Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate | Biotech Hunter

Enrollment

142

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

Arthroplasty, ReplacementPrevention of Venous ThromboembolismModerate Renal Impairment (CrCl 30-50 mL/Min)

Interventions

DRUG

Dabigatran etexilate

once daily approved dose by EMEA and Health Canada

Trial Locations (10)

1160.86.43001 Boehringer Ingelheim Investigational Site, Graz

1160.86.43003 Boehringer Ingelheim Investigational Site, Vienna

1160.86.01001 Boehringer Ingelheim Investigational Site, Red Deer

1160.86.01002 Boehringer Ingelheim Investigational Site, Halifax

1160.86.01003 Boehringer Ingelheim Investigational Site, Charlottetown

1160.86.42002 Boehringer Ingelheim Investigational Site, Prague

1160.86.35801 Boehringer Ingelheim Investigational Site, Jyväskylä

1160.86.31002 Boehringer Ingelheim Investigational Site, Hilversum

1160.86.46002 Boehringer Ingelheim Investigational Site, Hässleholm

1160.86.46001 Boehringer Ingelheim Investigational Site, Mölndal